SG Americas Securities LLC Has $1.91 Million Holdings in Boston Scientific Co. (NYSE:BSX)

SG Americas Securities LLC trimmed its holdings in Boston Scientific Co. (NYSE:BSXGet Rating) by 70.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,088 shares of the medical equipment provider’s stock after selling 104,376 shares during the period. SG Americas Securities LLC’s holdings in Boston Scientific were worth $1,908,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BSX. Norges Bank acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $563,108,000. Marshall Wace LLP raised its position in shares of Boston Scientific by 572.2% in the fourth quarter. Marshall Wace LLP now owns 6,357,680 shares of the medical equipment provider’s stock valued at $270,075,000 after buying an additional 5,411,822 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $152,629,000. Assenagon Asset Management S.A. raised its position in shares of Boston Scientific by 52.3% in the first quarter. Assenagon Asset Management S.A. now owns 3,078,389 shares of the medical equipment provider’s stock valued at $136,342,000 after buying an additional 1,057,577 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its position in shares of Boston Scientific by 75.3% in the fourth quarter. Point72 Asset Management L.P. now owns 1,902,978 shares of the medical equipment provider’s stock valued at $80,839,000 after buying an additional 817,400 shares in the last quarter. 90.48% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

NYSE BSX opened at $38.00 on Tuesday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.78 and a current ratio of 1.18. Boston Scientific Co. has a fifty-two week low of $34.98 and a fifty-two week high of $47.49. The stock has a market cap of $54.32 billion, a PE ratio of 71.70, a PEG ratio of 2.07 and a beta of 0.83. The firm’s fifty day moving average price is $38.21 and its two-hundred day moving average price is $41.47.

Boston Scientific (NYSE:BSXGet Rating) last issued its quarterly earnings data on Wednesday, April 27th. The medical equipment provider reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.01. Boston Scientific had a net margin of 6.65% and a return on equity of 14.51%. The company had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $2.95 billion. During the same quarter in the previous year, the firm posted $0.37 earnings per share. Boston Scientific’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, equities analysts expect that Boston Scientific Co. will post 1.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BSX. Morgan Stanley dropped their price target on shares of Boston Scientific from $51.00 to $46.00 and set an “overweight” rating for the company in a research report on Friday, July 15th. Wolfe Research initiated coverage on shares of Boston Scientific in a research report on Tuesday, July 5th. They set an “outperform” rating and a $43.00 price objective for the company. Citigroup lowered their price objective on shares of Boston Scientific from $52.00 to $47.00 and set a “buy” rating for the company in a research report on Tuesday, May 17th. BTIG Research lowered their price objective on shares of Boston Scientific from $52.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, June 24th. Finally, Canaccord Genuity Group lowered their price objective on shares of Boston Scientific from $51.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, June 29th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.42.

Insider Buying and Selling

In other Boston Scientific news, EVP Wendy Carruthers sold 7,500 shares of the company’s stock in a transaction on Friday, June 24th. The shares were sold at an average price of $38.00, for a total transaction of $285,000.00. Following the sale, the executive vice president now owns 132,413 shares of the company’s stock, valued at $5,031,694. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 22,500 shares of company stock valued at $865,725 over the last 90 days. 0.66% of the stock is owned by insiders.

Boston Scientific Company Profile

(Get Rating)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

Featured Stories

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXGet Rating).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.